Lamictal XR Monotherapy: Will Ex-U.S. Data Invalidate Historical Comparison?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA reviewers cite issues with the study design GSK used in its sNDA, but still find evidence of efficacy for partial seizures.
You may also be interested in...
Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials
GlaxoSmithKline’s anti-epileptic drug Lamictal XR gained approval for conversion to monotherapy without any post-marketing commitments despite concerns about the novel trial design employed for the application.
Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials
GlaxoSmithKline’s anti-epileptic drug Lamictal XR gained approval for conversion to monotherapy without any post-marketing commitments despite concerns about the novel trial design employed for the application.
FDA Encourages Sponsors Of Hypertension Drugs To Promote Their Cardiovascular Benefits
Final guidance allowing class-wide outcomes claims includes suggested language for both advertising and labeling.